Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

这家德国生物科技公司第四季度每股收益达到€1.08，超过分析师预期。营收为€11.9亿，高于€11.2亿的市场预期。 2024财年，BioNTech录得净亏损€6.653亿，即每股亏损€2.77，而2023年同期为净利润€9.303亿，每股收益€3.83。全年营收从上年的€38.2亿下降至€27.5亿。

周一，Jefferies重申了对BioNTech SE（NASDAQ:BNTX）的股票评级和目标价，维持买入评级，目标价为149.00美元。此次重申是在该公司最新季度财报发布后做出的。财报显示，公司收入约为11.9亿欧元，略高于市场预期的11.8亿欧元。得益于运营支出的降低，每股收益（EPS）达到1.08欧元，同样超过了市场预期的0.77欧元。根据 InvestingPro ...

In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

In a report released today, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of ...